TCL.AU

13.62

+0.67%↑

BXB.AU

20.31

-0.34%↓

COL.AU

21.06

+3.95%↑

QAN.AU

8.41

-2.1%↓

CAR.AU

31.31

-4.37%↓

TCL.AU

13.62

+0.67%↑

BXB.AU

20.31

-0.34%↓

COL.AU

21.06

+3.95%↑

QAN.AU

8.41

-2.1%↓

CAR.AU

31.31

-4.37%↓

TCL.AU

13.62

+0.67%↑

BXB.AU

20.31

-0.34%↓

COL.AU

21.06

+3.95%↑

QAN.AU

8.41

-2.1%↓

CAR.AU

31.31

-4.37%↓

TCL.AU

13.62

+0.67%↑

BXB.AU

20.31

-0.34%↓

COL.AU

21.06

+3.95%↑

QAN.AU

8.41

-2.1%↓

CAR.AU

31.31

-4.37%↓

TCL.AU

13.62

+0.67%↑

BXB.AU

20.31

-0.34%↓

COL.AU

21.06

+3.95%↑

QAN.AU

8.41

-2.1%↓

CAR.AU

31.31

-4.37%↓

Search

CSL Ltd

Geschlossen

BrancheIndustrie

256.52 -0.19

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

255.69

Max

262.02

Schlüsselkennzahlen

By Trading Economics

Einkommen

1.3B

2B

Verkäufe

1.5B

8.2B

KGV

Branchendurchschnitt

28.972

33.198

EPS

1.831

Dividendenrendite

1.7

Gewinnspanne

24.437

Angestellte

32,698

EBITDA

1.5B

3.2B

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+24.26% upside

Dividenden

By Dow Jones

Dividendenrendite

Branchendurchschnitt

1.70%

2.54%

Nächste Dividendenausschüttung

9. Apr. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-14B

121B

Vorheriger Eröffnungskurs

256.71

Vorheriger Schlusskurs

256.52

Nachrichtenstimmung

By Acuity

50%

50%

219 / 468 Ranking in Industrials

CSL Ltd Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

10. Feb. 2025, 21:55 UTC

Ergebnisse

CSL Lifts 1st Half Net Profit by 3%, Led by Blood-Plasma Business -- Update

10. Feb. 2025, 21:34 UTC

Ergebnisse

CSL Lifts 1st Half Net Profit by 3%, Led by Blood-Plasma Business

12. Aug. 2024, 23:23 UTC

Ergebnisse

CSL Annual Profit Rises by 20% on Immunoglobulins Growth -- Update

12. Aug. 2024, 22:49 UTC

Ergebnisse

CSL Annual Profit Rises by 20%, Forecasts Fiscal Year 2025 Underlying Earnings Growth

21. März 2025, 02:03 UTC

Market Talk

Severe U.S. Influenza Season Could Benefit CSL -- Market Talk

11. Feb. 2025, 22:30 UTC

Market Talk

Flu Vaccines Proving Problematic for CSL -- Market Talk

10. Feb. 2025, 21:40 UTC

Ergebnisse

CSL Lifts 1H Net Profit by 3%, Led by Blood-Plasma Business -- Update

10. Feb. 2025, 21:19 UTC

Ergebnisse

CSL Lifts 1H Net Profit by 3%, Led by Blood-Plasma Business

10. Feb. 2025, 21:13 UTC

Ergebnisse

CSL Reaffirms Guidance for FY 2025 Net Profit of US$3.2 Billion-US$3.3 Billion at Constant FX

10. Feb. 2025, 21:12 UTC

Ergebnisse

CSL Interim Dividend US$1.30/Security

10. Feb. 2025, 21:12 UTC

Ergebnisse

CSL 1H Revenue US$8.48 Billion, Up 5% on Year

10. Feb. 2025, 21:11 UTC

Ergebnisse

CSL 1H Net Profit US$2.07 Billion, Up 3% on Year

7. Nov. 2024, 03:53 UTC

Market Talk

U.S. Tariffs Could Force Moves by Australian Med-Techs -- Market Talk

22. Okt. 2024, 22:53 UTC

Market Talk

CSL's R&D Update Seen as Neutral Overall -- Market Talk

10. Okt. 2024, 22:20 UTC

Market Talk

CSL Bull Looking for Update on Gross Margin -- Market Talk

13. Aug. 2024, 00:33 UTC

Market Talk

CSL Profit Outlook Looks Weaker Than Expected -- Market Talk

12. Aug. 2024, 22:34 UTC

Ergebnisse

CSL Annual Profit Rises by 20%, Forecasts FY 2025 Underlying Earnings Growth

12. Aug. 2024, 22:18 UTC

Ergebnisse

CSL Expects FY2025 Revenue Growth of Roughly 5%-7% at Constant Currency

12. Aug. 2024, 22:18 UTC

Ergebnisse

CSL: Conditions for Seqirus Remain Challenging, But Unit Expected to Outperform Market

12. Aug. 2024, 22:17 UTC

Ergebnisse

CSL: Has a Number of Efficiency Initiatives Underway in Plasma Collections, Manufacturing Operations

12. Aug. 2024, 22:16 UTC

Ergebnisse

CSL: Momentum in Behring Seen Underpinned by Strong Patient Demand in Immunoglobulins

12. Aug. 2024, 22:15 UTC

Ergebnisse

CSL: Remains Confident in Medium-Term Double-Digit Earnings Growth Target

12. Aug. 2024, 22:14 UTC

Ergebnisse

CSL: Vifor Continues to Grow Iron Volume in Europe Despite Generic Entrants

12. Aug. 2024, 22:13 UTC

Ergebnisse

CSL Expects FY2025 Underlying Profit Up Between 10%-13% on Constant Currency Basis

12. Aug. 2024, 22:13 UTC

Ergebnisse

CSL Expects FY2025 Underlying Profit Between US$3.2 Billion-US$3.3 Billion

12. Aug. 2024, 22:11 UTC

Ergebnisse

CSL: Outlook for Behring Positive But Competitive Pressures Increased Recently

12. Aug. 2024, 22:10 UTC

Ergebnisse

CSL FY Underlying Profit Up 15% on Constant Currency Basis to US$3.01 Billion

12. Aug. 2024, 22:09 UTC

Ergebnisse

CSL FY Revenue US$14.80 Billion, Up 11% On-Year

12. Aug. 2024, 22:08 UTC

Ergebnisse

CSL FY Underlying Profit US$2.91 Billion, Up 11% On-Year

12. Aug. 2024, 22:07 UTC

Ergebnisse

CSL FY Net Profit US$2.64 Billion, Up 20% On-Year

Peer-Vergleich

Kursveränderung

CSL Ltd Prognose

Kursziel

By TipRanks

24.26% Vorteil

12-Monats-Prognose

Durchschnitt 317.1 AUD  24.26%

Hoch 360.3 AUD

Tief 250 AUD

Basierend auf 14 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für CSL Ltd – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

14 ratings

12

Buy

2

Halten

0

Sell

Stimmung

By Acuity

219 / 468 Ranking in Industrie

Nachrichtenstimmung

Neutral

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Überdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über CSL Ltd

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants. The CSL Seqirus segment provides influenza related products and pandemic services to governments. The CSL Vifor segment offers products in the therapeutic areas of iron deficiency and nephrology. The company also licenses CSL intellectual property. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia.